Hepatitis A booster vaccination: is there a need?

被引：149

作者：

Van Damme, P ^{[1
]}

Banatvala, J ^{[1
]}

Fay, O ^{[1
]}

Iwarson, S ^{[1
]}

McMahon, B ^{[1
]}

Van Herck, K ^{[1
]}

Shouval, D ^{[1
]}

Bonanni, P ^{[1
]}

Connor, B ^{[1
]}

Cooksley, G ^{[1
]}

Leroux-Roels, G ^{[1
]}

Von Sonnenburg, F ^{[1
]}

机构：

[1] Univ Instelling Antwerp, Ctr Evaluat Vaccinat, WHO,Unit Epidemiol & Social Med, Collaborating Ctr Control & Prevent Viral Hepatit, B-2610 Antwerp, Belgium

来源：

LANCET | 2003年 / 362卷 / 9389期

关键词：

D O I：

10.1016/S0140-6736(03)14418-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hepatitis A is one of the most common vaccine-preventable infectious diseases in the world. Effective vaccines against hepatitis A have been available since 1992, and they provide long-term immunity against the infection. However, there is no worldwide consensus on how long protection will last or whether there will be a need for hepatitis A virus (HAV) booster vaccinations in the future. In most countries, booster-vaccination policy is guided by manufacturers' recommendations, national authorities, or both. In June, 2002, a panel of international experts met to review the long-term immunogenicity and protection conferred by HAV vaccine in different population groups. Data have shown that after a full primary vaccination course, protective antibody amounts persist beyond 10 years in healthy individuals, and underlying immune memory provides protection far beyond the duration of anti-HAV antibodies. The group concluded that there is no evidence to lend support to HAV booster vaccination after a full primary vaccination course in a healthy individual. However, further investigations are needed before deciding if boosters can be omitted in special patient-groups.

引用

页码：1065 / 1071

页数：7

共 76 条

[1] Efficacy of hepatitis A vaccination in children aged 12 to 24 months [J].